Edition:
United States

Biosyent Inc (RX.V)

RX.V on TSX Venture Exchange

7.30CAD
22 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.30
Open
$7.10
Day's High
$7.30
Day's Low
$7.10
Volume
21,428
Avg. Vol
12,890
52-wk High
$9.12
52-wk Low
$6.75

Latest Key Developments (Source: Significant Developments)

Biosyent Q4 earnings per share C$0.08
Wednesday, 15 Mar 2017 08:00am EDT 

Biosyent Inc : Biosyent releases results for fourth quarter and full year 2016 . Q4 earnings per share C$0.08 . Q4 revenue rose 30 percent to c$5.01 million .Biosyent Inc - as at December 31, 2016, company had cash, cash equivalents, and short term investments totalling C$13.7 million.  Full Article

Biosyent Q2 fully diluted EPS $0.07
Friday, 12 Aug 2016 08:00am EDT 

Biosyent Inc : Q2 2016 net revenues of $4.4 million, up 22% versus Q2 2015 .Biosyent Inc says Q2 fully diluted EPS was $0.07.  Full Article

BioSyent Q1 earnings per share C$0.07
Friday, 27 May 2016 08:00am EDT 

BioSyent Inc : BioSyent releases Q1 2016 results . Q1 earnings per share C$0.07 .Q1 revenue rose 14 percent to C$3.772 million.  Full Article

Biosyent signs distribution agreement for new cardiovascular products
Wednesday, 25 May 2016 12:53pm EDT 

Biosyent Inc: Biosyent signs exclusive distribution agreement for two new cardiovascular products . Intends to submit dossier seeking marketing approval of products to Health Canada in 2016 .Forecasts that the new products will add approximately CAD $20 million to overall revenue of company when they reach "peak sales".  Full Article

BioSyent Inc receives Health Canada approval for new urgent care product using aguettant system
Thursday, 5 May 2016 08:00am EDT 

BioSyent Inc:Says its subsidiary, BioSyent Pharma Inc has received approval from Health Canada for a new urgent care product, phenylephrine hydrochloride injection in Aguettant System pre-filled syringe, for use in hospitals and acute care settings.  Full Article

Biosyent Pharma acquires exclusive rights For Cysview In Canada
Wednesday, 19 Aug 2015 08:00am EDT 

BioSyent Inc:Announces that its subsidiary BioSyent Pharma Inc. has signed an agreement with Photocure ASA granting BioSyent the exclusive rights for Cysview in Canada.  Full Article

More From Around the Web

BRIEF-Biosyent Q4 earnings per share C$0.08

* Biosyent releases results for fourth quarter and full year 2016